Dexrazoxane: A Cardioprotectant for Pediatric Cancer Patients Receiving Anthracyclines

Journal of Pediatric Oncology Nursing

Volumn 32, Issue 3, 2015, Pages 178-184

  Wu, Vivian ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

anthracyclines; cardioprotectants; dexrazoxane; pediatric cancers

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; PROTECTIVE AGENT; RAZOXANE;

ADOLESCENT; CARDIOTOXICITY; CHILD; FEMALE; HUMAN; INFANT; MALE; NEOPLASMS; PRESCHOOL CHILD;

ADOLESCENT; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CARDIOTOXICITY; CHILD; CHILD, PRESCHOOL; DEXRAZOXANE; FEMALE; HUMANS; INFANT; MALE; NEOPLASMS; PROTECTIVE AGENTS;

EID: 84930400895     PISSN: 10434542     EISSN: 15328457     Source Type: Journal    
DOI: 10.1177/1043454214554008     Document Type: Review

References (32)

1. About Pharmacology. (2012, October11). Pharmacology of dexrazoxane. Retrieved from http://www.about-pharmacology.com/?s=Pharmacology+of+Dexr
2. American Cancer Society. (2012, September20). What are the key statistics for childhood cancer? Retrieved from http://www.cancer.org/cancer/cancerinchildren/detailedguide/cancer-in-children-key-statistics
3. Barry E.,Alvarez J. A.,Scully R. E.,Miller T. L.,Lipshultz S. E.Anthracycline-induced cardiotoxicity: Course, pathophysiology, prevention and management.Expert Opinion on Pharmacotherapy. 2007;8:1039-1058
4. Barry E. V.,Vrooman L. M.,Dahlberg S. E.,Neuberg D. S.,Asselin B. L.,Athale U. H.,.. Silverman L. B.Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane.Journal of Clinical Oncology. 2008;26:1106-1111
5. Basser R. L.,Sobol M. M.,Duggan G.,Cebon J.,Rosenthal M. A.,Mihaly G.,Green M. D.Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patient with advanced malignancy.Journal of Clinical Oncology. 1994;12:1659-1666
6. Choi H. S.,Park E. S.,Kang H. J.,Shin H. Y.,Noh C. I.,Yun Y. S.,.. Choi J. Y.Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.Journal of Korean Medical Science. 2010;25:1336-1342
7. Cvetkovic R. S.,Scott L. J.Dexrazoxane: A review of its use for cardioprotection during anthracycline therapy.Drugs. 2005;65:1005-1024
8. Elbl L.,Hrstkova H.,Tomaskova I.,Michalek J.Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: Echocardiographic follow-up.Supportive Care in Cancer. 2006;14:128-136
9. Gianni L.,Herman E. H.,Lipshultz S. E.,Minotti G.,Sarvazyan N.,Sawyer D. B.Anthracycline cardiotoxicity: From bench to bedside.Journal of Clinical Oncology. 2008;26:3777-3784
10. Hellmann K.Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin’s disease: A claim without evidence.Journal of Clinical Oncology. 2007;25:4689-4690
11. Horenstein M. S.,Vander Heide R. S.,L’Ecuyer T. J.Molecular basis of anthracycline-induced cardiotoxicity and its prevention.Molecular Genetics and Metabolism. 2000;71:436-444
12. Kizek R.,Adam V.,Hrabeta J.,Eckschlager T.,Smutny S.,Burda J.,.. Stiborova M.Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances.Pharmacology & Therapeutics. 2012;133:26-39
13. Krischer J.,Epstein S.,Cuthbertson D.D.,Goorin A.M.,Epstein M.L.,Lipshultz S.E.Clinical Cardiotoxicity Following Anthracycline Treatment for Childhood Cancer: The Pediatric Oncology Group Experience.Journal of Clinical Oncology. 1997;15:1544-1552
14. Leonard R. C. F.,Williams S.,Tulpule A.,Levine A. M.,Oliveros S.Improving the therapeutic index of anthracycline therapy: Focus on liposomal doxorubicin.Breast. 2009;18:218-224
15. Lipshultz S. E.,Alvarez J. A.,Scully R. E.Anthracycline associated cardiotoxicity in survivors of childhood cancer.Heart. 2008;94:525-533
16. Lipshultz S. E.,Colan S. D.,Gelber R. D.,Perez-Atayde A. R.,Sallan S. E.,Sanders S. P.Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.New England Journal of Medicine. 1991;324:808-815
17. Lipshultz S. E.,Lipsitz S. R.,Orav E. J.Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin’s disease: A claim without compelling evidence.Journal of Clinical Oncology. 2007;25:3179
18. Lipshultz S. E.,Rifai N.,Dalton V. M.,Levy D. E.,Silverman L. B.,Lipsitz S. R.,..Sallan S. E.The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.New England Journal of Medicine. 2004;351:145-153
19. Lipshultz S. E.,Rifai N.,Sallan S. E.,Lipsitz S. R.,Dalton V.,Sacks D. B.,Ottlinger M. E.Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury.Circulation. 1997;96:2641-2648
20. Lipshultz S. E.,Scully R. E.,Lipsitz S. R.,Sallan S. E.,Silverman L. B.,Miller T. L.,.. Colan S. D.Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: Long-term follow-up of a prospective, randomised, multicentre trial.Lancet Oncology. 2010;11:950-961
21. Mariotto A. B.,Rowland J. H.,Yabroff K. R.,Scoppa S.,Hachey M.,Ries L.,Feurer E. J.Long-term survivors of childhood cancers in the United States.Cancer Epidemiology, Biomarkers & Prevention. 2009;355:1572-1582
22. Minotti G.,Menna P.,Salvatorelli E.,Cairo G.,Gianni L.Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.Pharmacological Reviews. 2004;56:185-229
23. Moghrabi A.,Levy D. E.,Asselin B.,Barr R.,Clavell L.,Hurwitz C.,.. Silverman L. B.Results of the Dana-Farber Cancer Institute ALL consortium protocol 95-01 for children with acute lymphoblastic leukemia.Blood. 2007;109:896-904
24. Nicolay K.,van der Neut R.,Fok J. J.,de Kruijff B.Effects of adriamycin on lipid polymorphism in cardiolipin-containing model and mitochondrial membranes.Biochimica et Biophysica Acta. 1985;819:55-65
25. Oeffinger K. C.,Mertens A. C.,Sklar C. A.,Kawashima T.,Hudson M. M.,Meadows A. T.,..Robison L. L.Chronic health conditions in adult survivors of childhood cancer.New England Journal of Medicine. 2006;355:1572-1582
26. Reulen R. C.,Winter D. L.,Frobisher C.,Lancashire E. R.,Stiller C. A.,Jenney M. E.,..Hawkins M. M.Long-term cause-specific mortality among survivors of childhood cancer.Journal of the American Medical Association. 2010;304:172-179
27. Schuchter L. M.,Hensley M. L.,Meropol N. J.,Winer E. P.2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: Clinical practice guidelines of the American Society of Clinical Oncology.Journal of Clinical Oncology. 2002;20:2895-2903
28. Sepe D. M.,Ginsberg J. P.,Balis F. M.Dexrazoxane as a cardioprotectant in children receiving anthracyclines.The Oncologist. 2010;15:1220-1226
29. Seymour L.,Bramwell V.,Moran L. A.Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer.Cancer Prevention Control. 1999;3:145-159
30. Tebbi C. K.,London W. B.,Friedman D.,Villaluna D.,De Alarcon P. A.,Constine L. S.,..Schwartz C. L.Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s disease.Journal of Clinical Oncology. 2007;25:493-500
31. van Dalen E.,Caron H.,Dickinson H. O.,Kremer L. C.Cardioprotective interventions for cancer patients receiving anthracyclines.Cochrane Database of Systemic Reviews. 2008;16:
32. Wexler L. H.,Andrich M. P.,Venzon D.,Berg S. L.,Weaver-McClure L.,Chen C. C.,.. Horowitz M. E.Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin.Journal of Clinical Oncology. 1996;14:362-372